The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1593
ISSUE1593
March 9, 2020
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
Download PDF: US English
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40
Disclosures
Principal Faculty- Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
- Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
- Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
- F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
- Describe the recently reported adverse effect associated with use of brolucizumab (Beovu) or treatment of macular degeneration.
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue.1 On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.2
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article